NCT04660929 is a Phase 1 clinical trial of CT-0508 in HER2-positive, sponsored by Carisma Therapeutics Inc.

Who is sponsoring NCT04660929?

NCT04660929 is sponsored by Carisma Therapeutics Inc.

What drugs are being tested in NCT04660929?

Interventions in NCT04660929: CT-0508, Pembrolizumab.

What condition does NCT04660929 study?

NCT04660929 studies HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell.

Is NCT04660929 still recruiting?

NCT04660929 is currently active, enrolled. Last updated 18 December 2024.

Last reviewed 2024-12-18 · How we verify

NCT04660929

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Active, enrolled Phase 1 Last updated 18 December 2024

What this trial tests

Phase 1 trial testing CT-0508 in HER2-positive in 48 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 February 2021

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Carisma Therapeutics Inc
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	2 February 2021
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	7 locations across United States

Drugs / interventions tested

CT-0508 — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

HER2-positive — all drugs for HER2-positive →
Adenocarcinoma — all drugs for Adenocarcinoma →
Bile Duct Cancer — all drugs for Bile Duct Cancer →
Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

Carisma Therapeutics Inc — full company profile →

Who can join

18 and older, any sex, with HER2-positive or Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Macrophages as tools and targets in cancer therapy.
Mantovani A, Allavena P, Marchesi F, Garlanda C. · · 2022 · cited 1279× · PMID 35974096 · DOI 10.1038/s41573-022-00520-5
Gastric cancer treatment: recent progress and future perspectives.
Guan WL, He Y, Xu RH. · · 2023 · cited 639× · PMID 37245017 · DOI 10.1186/s13045-023-01451-3
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K, Farrukh H, Chittepu VCSR, Xu H, et al · · 2022 · cited 478× · PMID 35361234 · DOI 10.1186/s13046-022-02327-z
Targeting macrophages in cancer immunotherapy.
Duan Z, Luo Y. · · 2021 · cited 462× · PMID 33767177 · DOI 10.1038/s41392-021-00506-6
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM, Merhi M, Inchakalody VP, Mestiri S, et al · · 2023 · cited 421× · PMID 36717905 · DOI 10.1186/s12943-023-01723-z
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei YQ, Wei XW. · · 2022 · cited 386× · PMID 35585567 · DOI 10.1186/s13045-022-01282-8
Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
Cheng K, Cai N, Zhu J, Yang X, et al · · 2022 · cited 289× · PMID 36069342 · DOI 10.1002/cac2.12345
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, et al · · 2021 · cited 217× · PMID 34568831 · DOI 10.1158/2643-3230.bcd-21-0084

Verify or expand the search:

Other recruiting trials for HER2-positive

Currently open trials in the same condition.

NCT07108127 — Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Tre · Phase 2 · recruiting
NCT06254807 — CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors · Phase 1 · active not recruiting
NCT05035836 — A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive · Phase 2 · recruiting

Other Carisma Therapeutics Inc trials

Trials by the same sponsor.

NCT06254807 — CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04660929 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carisma Therapeutics Inc
Last refreshed: 18 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04660929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing